Dr. Reddy's Denmark ApS
APSActiveAdvertising protectionCVR 45121895Delta Park 45, 2665 Vallensbæk StrandManufacture of other food products n.e.c.· NACE 1089Est. 2024 · 1 year old14 employees
Loading company…
Overview
Dr. Reddy's Denmark ApS is a Danish APS based in Vallensbæk Strand, operating in the Manufacture of other food products n.e.c. sector. Incorporated in 2024, the company has 14 employees and reported revenue of DKK 226.6m in its latest annual filing.
Revenue 2025
226.6M DKK
EBITDA margin
5.4 %
Net profit 2025
7M DKK
14 employees
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
4.9 %
Very weakAmong the 20% lowest rated companies in the industry
20252025
Liquidity ratioCurrent assets ÷ Short-term debt
1.0×
WeakAmong the 30% lowest rated companies in the industry
20252025
Return on assets (ROA)Net profit ÷ Total assets × 100
3.8 %
AverageAround the average of companies in the same industry
20252025
EBITDA — year on year
DKK millionsKey figures
Annual report 2025| Revenue | 226.6M DKK | — |
| EBITDA | 12.2M DKK | — |
| Net profit | 7M DKK | — |
| Total assets | 186.1M DKK | — |
| Equity | 9M DKK | — |
| Employees | 14 | — |
Company information
Legal name
Dr. Reddy's Denmark ApS
CVR number
45121895
Legal form
Anpartsselskab
NACE code
Founded
4 October 2024 · 1 year
Share capital
DKK 41,000
Employees
14 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to direktører i forening.
Company purpose
Selskabets formål er produktion af farmaceutiske og bioteknologiske produkter, erhvervelse, brug, køb og salg af varer af enhver art og i særdeleshed af intellektuelle ejendomsrettigheder og hermed beslægtede aktiviteter.
(no translation available)
Contact
Address
Delta Park 45, 2665 Vallensbæk Strand
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Dr. Reddy's Denmark ApS reported revenue of DKK 226.6m. The bottom line showed a net profit of DKK 7.0m, and the EBITDA margin stood at 5.4%.
At the end of 2025, equity financed 4.9% of the balance sheet, and current assets covered short-term debt 1 times.
Financials
Revenue
DKK millionsEBITDA
DKK millionsIncome statement
DKK thousands| Item | 2025 |
|---|---|
| Revenue | 226,616 |
| Staff expenses | -14,536 |
| EBITDA | 12,196 |
| Depreciation & amort. | -382 |
| EBIT | 11,814 |
| Net financials | -2,498 |
| Profit before tax | 9,316 |
| Tax | 2,276 |
| Net profit | 7,040 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2025 |
|---|---|
| Total assets | 186,090 |
| Equity | 9,040 |
| Long-term debt | 1,664 |
| Short-term debt | 175,387 |
| Total debt | 177,050 |
Financial ratios
5-year trendEBITDA margin
5.4 %
20252025
Equity ratio
4.9 %
Very weakAmong the 20% lowest rated companies in the industry
20252025
Return on equity
77.9 %
Very strongAmong the 10% highest rated companies in the industry
20252025
Net profit margin
3.1 %
AverageAround the average of companies in the same industry
20252025
Asset turnover
1.22×
AverageAround the average of companies in the same industry
20252025
Debt / equity
19.59×
Very weakAmong the 10% lowest rated companies in the industry
20252025
Sector performance
24 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginAverage
Around the average of companies in the same industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginAverage
Around the average of companies in the same industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginAverage
Around the average of companies in the same industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Very strong
Among the 10% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very strong
Among the 10% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Average
Around the average of companies in the same industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioStrong
Among the 40% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 30% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 30% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioWeak
Among the 40% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalAverage
Around the average of companies in the same industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioStrong
Among the 30% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery weak
Among the 20% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 20% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 10% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 10% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtAverage
Around the average of companies in the same industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 40% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageAverage
Around the average of companies in the same industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverAverage
Around the average of companies in the same industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverVery strong
Among the 20% highest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's equity.
One-year change in debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
AT Management | Management | 2025 |
MP Chief Executive Officer | Chief Executive Officer | 2025 |
MK Management | Management | 2025 |
MG Founder | Founder | 2024 |
Former (2)
KR Management | Management | 2024 – 2025 |
PA Management | Management | 2024 – 2025 |
Board of directors
Non-executive oversightNo data on file.
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
Dr. Reddy's Laboratories SA | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Dr. Reddy's Laboratories SA100%
Dr. Reddy's Denmark ApS (this company)Board network connections
Board members of Dr. Reddy's Denmark ApS also hold positions in 39 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mette Gade | Founder | 39 companiesMany roles |
Frequently asked questions
What is the CVR number of Dr. Reddy's Denmark ApS?
Dr. Reddy's Denmark ApS is registered with CVR / Virk under CVR 45121895.
What is the revenue of Dr. Reddy's Denmark ApS?
Dr. Reddy's Denmark ApS reported revenue of DKK 226.6m in 2025.
How many employees does Dr. Reddy's Denmark ApS have?
Dr. Reddy's Denmark ApS employs 14 people as of the latest annual report.
Who is the CEO of Dr. Reddy's Denmark ApS?
Michael Pedersen is the CEO of Dr. Reddy's Denmark ApS, in role since 2025.
Where is Dr. Reddy's Denmark ApS headquartered?
Dr. Reddy's Denmark ApS's registered address is Delta Park 45.